SA111330060B1 - أجسام مضادة ضد notch1 - Google Patents

أجسام مضادة ضد notch1 Download PDF

Info

Publication number
SA111330060B1
SA111330060B1 SA111330060A SA111330060A SA111330060B1 SA 111330060 B1 SA111330060 B1 SA 111330060B1 SA 111330060 A SA111330060 A SA 111330060A SA 111330060 A SA111330060 A SA 111330060A SA 111330060 B1 SA111330060 B1 SA 111330060B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
rat
antibodies
human
notch
Prior art date
Application number
SA111330060A
Other languages
Arabic (ar)
English (en)
Inventor
كينث جي.جيلز
بين ـ بينج ستيفن زهو
ليودميلا جناديفنا تشيستيكوفا
يجي جاو
جويل بارد
Original Assignee
ويث ال ال سي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ويث ال ال سي filed Critical ويث ال ال سي
Publication of SA111330060B1 publication Critical patent/SA111330060B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
SA111330060A 2010-12-15 2011-12-14 أجسام مضادة ضد notch1 SA111330060B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US201161552578P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
SA111330060B1 true SA111330060B1 (ar) 2015-06-04

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
SA111330060A SA111330060B1 (ar) 2010-12-15 2011-12-14 أجسام مضادة ضد notch1

Country Status (19)

Country Link
US (2) US9127060B2 (https=)
EP (1) EP2651977A2 (https=)
JP (1) JP6016800B2 (https=)
KR (2) KR20150088334A (https=)
CN (2) CN105884896A (https=)
AR (1) AR084315A1 (https=)
AU (2) AU2011342799B2 (https=)
BR (1) BR112013015122A2 (https=)
CA (1) CA2821130C (https=)
CO (1) CO6791565A2 (https=)
MX (1) MX346995B (https=)
NZ (1) NZ611785A (https=)
PE (1) PE20141109A1 (https=)
PH (2) PH12013501255A1 (https=)
RU (1) RU2622083C2 (https=)
SA (1) SA111330060B1 (https=)
SG (1) SG191039A1 (https=)
TW (1) TWI471333B (https=)
WO (1) WO2012080926A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
JP6059985B2 (ja) 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体
SG191039A1 (en) 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
WO2014047426A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
HK1214282A1 (zh) 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
EP3856343A1 (en) * 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1544210A4 (en) 2002-07-18 2006-01-25 Masayasu Okochi NEW NOTCH ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS FOR WHICH THEY ARE USED
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
EP1709150A4 (en) 2003-11-26 2007-11-21 Health Research Inc USE OF NOTCH-INTERFERING MEDICAMENTS FOR THE TREATMENT OF PLASMA-CELL-RELATED DISEASES
WO2006001956A2 (en) 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
AU2005302846A1 (en) * 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
US20080206753A1 (en) 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
CN101605815B (zh) * 2006-12-18 2013-11-13 健泰科生物技术公司 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
JP6059985B2 (ja) 2009-06-18 2017-01-11 ファイザー・インク 抗ｎｏｔｃｈ−１抗体
CA2775880A1 (en) 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
SG191039A1 (en) 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies

Also Published As

Publication number Publication date
CN105884896A (zh) 2016-08-24
PH12013501255A1 (en) 2013-08-05
CA2821130C (en) 2017-11-07
JP6016800B2 (ja) 2016-10-26
TW201302787A (zh) 2013-01-16
WO2012080926A3 (en) 2012-10-04
US20130266594A1 (en) 2013-10-10
JP2014503205A (ja) 2014-02-13
KR20130108430A (ko) 2013-10-02
CN103547594B (zh) 2016-05-11
EP2651977A2 (en) 2013-10-23
KR20150088334A (ko) 2015-07-31
PH12017500864A1 (en) 2017-12-11
CN103547594A (zh) 2014-01-29
TWI471333B (zh) 2015-02-01
RU2013126494A (ru) 2015-01-20
AU2016219704A1 (en) 2016-09-15
KR101580726B1 (ko) 2015-12-29
RU2622083C2 (ru) 2017-06-09
MX2013006875A (es) 2013-07-05
AU2011342799A1 (en) 2013-07-04
SG191039A1 (en) 2013-08-30
MX346995B (es) 2017-04-06
PE20141109A1 (es) 2014-09-24
US9127060B2 (en) 2015-09-08
CO6791565A2 (es) 2013-11-14
HK1194388A1 (zh) 2014-10-17
AR084315A1 (es) 2013-05-08
WO2012080926A2 (en) 2012-06-21
BR112013015122A2 (pt) 2017-05-30
NZ611785A (en) 2015-04-24
CA2821130A1 (en) 2012-06-21
AU2011342799B2 (en) 2016-06-09
US20160002331A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
SA111330060B1 (ar) أجسام مضادة ضد notch1
US20220002415A1 (en) Antibody Therapeutics that Bind CTLA4
JP6755866B2 (ja) Ｃｄ７３特異的結合分子及びその使用
SA516371109B1 (ar) 1a أجسام مضادة خاصة لمركب ترابطي يشبه عامل تنكرز ورم وتركيباتها واستخدامها
CN110431231A (zh) 抗-cd3抗体和包含所述抗体的分子
EP3445784B1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
JP7843824B2 (ja) 抗体および使用方法
US20220387417A1 (en) Pharmaceutical Combination and Use Thereof
JP7384668B2 (ja) 細胞傷害性ｔ細胞枯渇用組成物
HK40066445A (en) Antibody therapeutics that bind ctla4
CN117396511A (zh) 靶向cd47和pd-l1的双特异性抗体及其使用方法
HK1226752A (en) Anti-notch1 antibodies
HK1226752A1 (en) Anti-notch1 antibodies